Viking Therapeutics among potential buyout candidates: Oppenheimer
Source: SeekingAlpha
2025-01-03 11:21:15 ET
More on Arcellx, Blueprint Medicines , etc.
- Viking Therapeutics: Competition Fears Are Exaggerated
- Viking Therapeutics: Holiday Gift
- Viking Therapeutics: Caution Ahead Of Novo's CagriSema Readout (Rating Downgrade)
- Merck-Hansoh deal for oral GLP-1 hurts obesity drug developers
- Janux Therapeutics prices $350M securities offering
Read the full article on Seeking Alpha
For further details see:
Viking Therapeutics among potential buyout candidates: Oppenheimer
Janux Therapeutics Inc.
NASDAQ: JANX
JANX Trading
-0.68% G/L:
$14.64 Last:
514,387 Volume:
$14.74 Open:
JANX Latest News
May 07, 2026 04:01:00 pm
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
April 27, 2026 04:01:00 pm
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
April 16, 2026 04:01:00 pm
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
JANX Stock Data
$789,139,228
45,531,890
1.75%
55
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
